JCR Pharmaceuticals says Japan grants orphan drug status to givinostat
Japan's health ministry also gave givinostat Priority Examination status for Duchenne muscular dystrophy. JCR targets a Japan marketing application by end-2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.